Expert insight into the diagnostic markers and challenges of BPDCN, including the importance of involving dermatologists and pathologists, to identify various disease presentations in both adult and pediatric patients.
Antibody-Drug Conjugates Continue to Transform the Oncology Landscape
May 28th 2024In part 1 of our 3-part series, antibody-drug conjugates are revolutionizing oncology, targeting cancer cells precisely. Agents like T-DM1, T-DXd, and sacituzumab govitecan continue to change the field.
Read More
Why Physicians Recommend Tagraxofusp in BPDCN
May 20th 2024During a Case-Based Roundtable® event, Thomas W. LeBlanc, MD, MA, MHS, discusses why he recommends tagraxofusp-exrs for patients with blastic plasmacytoid dendritic cell neoplasm in need of treatment in the first article of a 2-part series.
Read More